196 related articles for article (PubMed ID: 29164956)
1. Have we successfully implemented CYP2D6 genotyping in psychiatry?
de Leon J
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1201-1203. PubMed ID: 29164956
[No Abstract] [Full Text] [Related]
2. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice.
Mrazek DA
CNS Spectr; 2006 Mar; 11(3 Suppl 3):3-4. PubMed ID: 17760222
[No Abstract] [Full Text] [Related]
3. Implementation of CYP2D6 genotyping in psychiatry.
Loovers HM; van der Weide J
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1065-77. PubMed ID: 19572825
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of pharmacogenetics in psychiatry].
Skrętkowicz J; Barańska M; Rychlik-Sych M
Wiad Lek; 2013; 66(2 Pt 2):185-91. PubMed ID: 25775815
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
Kirchheiner J; Rodriguez-Antona C
CNS Drugs; 2009; 23(3):181-91. PubMed ID: 19320528
[TBL] [Abstract][Full Text] [Related]
6. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
7. [Role of genetics in psychiatric treatment].
Hamdani N; Gorwood P
Presse Med; 2008 May; 37(5 Pt 2):902-11. PubMed ID: 18356009
[TBL] [Abstract][Full Text] [Related]
8. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation.
de Leon J
CNS Spectr; 2006 Mar; 11(3 Suppl 3):8-12. PubMed ID: 17760224
[No Abstract] [Full Text] [Related]
9. Personalized medicine in psychiatry: new technologies and approaches.
Costa e Silva JA
Metabolism; 2013 Jan; 62 Suppl 1():S40-4. PubMed ID: 23018148
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic monitoring of psychotropic drugs and pharmacogenetic tests in psychiatry].
Voirol P; Eap CB; Baumann P
Rev Med Suisse Romande; 2000 Feb; 120(2):99-104. PubMed ID: 10748694
[No Abstract] [Full Text] [Related]
12. Personalized pharmacotherapy in psychiatry.
Filaković P; Petek A
Psychiatr Danub; 2009 Sep; 21(3):341-6. PubMed ID: 19794353
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.
Crettol S; de Leon J; Hiemke C; Eap CB
Clin Pharmacol Ther; 2014 Mar; 95(3):254-7. PubMed ID: 24196844
[No Abstract] [Full Text] [Related]
14. Clinical applications of CYP genotyping in psychiatry.
Spina E; de Leon J
J Neural Transm (Vienna); 2015 Jan; 122(1):5-28. PubMed ID: 25200585
[TBL] [Abstract][Full Text] [Related]
15. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
Seripa D; Lozupone M; Stella E; Paroni G; Bisceglia P; La Montagna M; D'onofrio G; Gravina C; Urbano M; Priore MG; Lamanna A; Daniele A; Bellomo A; Logroscino G; Greco A; Panza F
Expert Opin Drug Saf; 2017 Dec; 16(12):1373-1385. PubMed ID: 29025271
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.
Vandel P; Talon JM; Haffen E; Sechter D
Curr Pharm Des; 2007; 13(2):241-50. PubMed ID: 17269931
[TBL] [Abstract][Full Text] [Related]
17. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
Herbild L; Bech M; Gyrd-Hansen D; Christensen M; Werge T; Nielsen KA
Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.
Peñas-Lledó EM; Llerena A
Br J Clin Pharmacol; 2014 Apr; 77(4):673-83. PubMed ID: 24033670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
